NCT04262466 2026-03-06Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsImmunocore LtdPhase 1/2 Active not recruiting410 enrolled
NCT03973333 2024-10-18Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabImmunocore LtdPhase 1/2 Withdrawn
NCT03515551 2022-03-11Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive CancersImmunocore LtdPhase 1/2 Terminated29 enrolled 25 charts